TABLE 2.
Variable | Comorbid condition
|
|||||
---|---|---|---|---|---|---|
Absent
|
Present
|
|||||
White women, % | Black women, % | P value | White women, % | Black women, % | P value | |
Diabetes mellitus | ||||||
| ||||||
Total, n | 275 | 193 | 81 | 78 | ||
| ||||||
Histologic group | < .001 | .051 | ||||
| ||||||
Type I | 75 | 56 | 73 | 56 | ||
| ||||||
Type II | 20 | 31 | 16 | 32 | ||
| ||||||
Type III | 6 | 13 | 11 | 12 | ||
| ||||||
Grade | < .001 | .007 | ||||
| ||||||
I | 55 | 31 | 53 | 33 | ||
| ||||||
II | 19 | 14 | 19 | 13 | ||
| ||||||
III | 26 | 55 | 28 | 53 | ||
| ||||||
International Federation of Gynecologists and Obstetricians stage | < .001 | .040 | ||||
| ||||||
I | 71 | 57 | 71 | 51 | ||
| ||||||
II | 13 | 12 | 8 | 14 | ||
| ||||||
III | 11 | 14 | 13 | 15 | ||
| ||||||
IV | 5 | 16 | 8 | 21 | ||
| ||||||
Obesity | ||||||
| ||||||
Total, n | 157 | 69 | 184 | 193 | ||
| ||||||
Histologic group | .001 | .006 | ||||
| ||||||
Type I | 74 | 50 | 73 | 58 | ||
| ||||||
Type II | 20 | 32 | 19 | 32 | ||
| ||||||
Type III | 6 | 18 | 8 | 10 | ||
| ||||||
Grade | < .001 | < .001 | ||||
| ||||||
I | 54 | 22 | 58 | 36 | ||
| ||||||
II | 19 | 13 | 19 | 15 | ||
| ||||||
III | 27 | 65 | 24 | 49 | ||
| ||||||
International Federation of Gynecologists and Obstetricians stage | .012 | .004 | ||||
| ||||||
I | 74 | 52 | 69 | 60 | ||
| ||||||
II | 8 | 15 | 15 | 12 | ||
| ||||||
III | 12 | 21 | 12 | 11 | ||
| ||||||
IV | 6 | 12 | 5 | 17 | ||
| ||||||
Hypertension | ||||||
| ||||||
Total, n | 151 | 65 | 205 | 206 | ||
| ||||||
Histologic group | .116 | .001 | ||||
| ||||||
Type I | 77 | 63 | 72 | 54 | ||
| ||||||
Type II | 16 | 26 | 22 | 34 | ||
| ||||||
Type III | 7 | 11 | 6 | 13 | ||
| ||||||
Grade | .004 | < .001 | ||||
| ||||||
I | 53 | 31 | 56 | 32 | ||
| ||||||
II | 21 | 19 | 18 | 13 | ||
| ||||||
III | 26 | 50 | 26 | 56 | ||
| ||||||
International Federation of Gynecologists and Obstetricians stage | .001 | .003 | ||||
| ||||||
I | 72 | 54 | 71 | 56 | ||
| ||||||
II | 12 | 10 | 12 | 13 | ||
| ||||||
III | 10 | 10 | 13 | 16 | ||
| ||||||
IV | 6 | 26 | 5 | 15 | ||
| ||||||
Other comorbid conditions | ||||||
| ||||||
Total, n | 208 | 140 | 148 | 128 | ||
| ||||||
Histologic group | .003 | .001 | ||||
| ||||||
Type I | 75 | 58 | 73 | 52 | ||
| ||||||
Type II | 19 | 36 | 19 | 28 | ||
| ||||||
Type III | 6 | 7 | 8 | 19 | ||
| ||||||
Grade | .003 | < .001 | ||||
| ||||||
I | 48 | 35 | 64 | 28 | ||
| ||||||
II | 21 | 16 | 16 | 12 | ||
| ||||||
III | 31 | 49 | 20 | 60 | ||
| ||||||
International Federation of Gynecologists and Obstetricians stage | .196 | < .001 | ||||
| ||||||
I | 71 | 64 | 72 | 47 | ||
| ||||||
II | 12 | 12 | 10 | 14 | ||
| ||||||
III | 10 | 11 | 13 | 19 | ||
| ||||||
IV | 6 | 13 | 5 | 21 |
The percentages may not total to 100 because of rounding.
Ruterbusch. Race, comorbidities, and endometrial cancer survival. Am J Obstet Gynecol 2014.